SEDIA® HIV-1 LAG-AVIDITY EIA
FOR DETERMINATION OF RECENCY OF INFECTION AND HIV-1 INCIDENCE ESTIMATION
Sedia® HIV-1 Limiting Antigen (LAg)-Avidity EIA
An in vitro single well quantitative limiting antigen avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Intended for use with liquid serum or plasma specimens.
For Research Use Only: Not for use in diagnostic procedures.
Gold Standard for Incidence
Independent evaluation by CEPHIA showed lowest false recency rate of any HIV incidence assay evaluated.*
Designed for Surveillance
Can be used to estimate HIV-1 incidence in a population, monitor and evaluate HIV intervention programs, and recognize those high-incidence populations. Ensures prevention research, vaccine trials, and resources are most appropriately utilized.
Catalog Number | Description |
---|---|
1002 | Sedia® HIV-1 LAg-Avidity EIA, For Research Use Only |
PRODUCT SPECIFICATIONS
Summary of Specifications | |
---|---|
Assay Time | 2-4 Hours |
Processing Temperature | 15° to 37°C (59° to 98.6°F) |
Storage Temperature | Refrigerator Pack: +2° to 8°C (35.6° to 46.4°F); Freezer Pack: -25° to -10°C (-13° to +14°F) |
Specimen Type | Human serum or plasma |
Specimen Volume | 5 µL |
Custom Antigen | Custom, multi-clade CDC “rIDR-M” HIV-1 gp41 antigen that provides for reduced HIV-1 subtype bias |
Mean Duration of Recent Infection | Approximately 130 days* |
False Recency Rate | Less than 1%** |
U.S. CDC Qualified | Each lot is performance tested by the U.S. Centers for Disease Control prior to market release |
For Research Use Only | Not for use in diagnostic procedures, RUO products are not to be used for diagnostic purposes, patient management, clinical purposes, or for investigational use within the U.S. |
HIV Status Requirement | Intended for use only with specimens previously diagnosed as HIV-1 positive |
Custom Antigen
The assay incorporates a custom multi-clade CDC “rIDR-M” HIV-1 gp41 antigen that provides for reduced HIV-1 subtype bias. Mean duration of recent infection approximately 130 days.*
*Duong YT, Kassanjee R, Welte A, et al. Recalibration of the Limiting Antigen Avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS ONE 2015, 10(2)e0114947.
U.S. CDC Tested
Each Sedia® HIV-1 LAg-Avidity EIA lot is performance tested by both Sedia’s Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of CDC testing can be provided upon request.
**Parekh B, Duong Y, Mavengere Y, et al. Performance of new LAg-Avidity EIA to measure HIV-1 incidence estimates and avidity maturation studies. PLoS ONE 2012, 7(3):e33328.
Independently Evaluated by CEPHIA
The Consortium for Evaluation and Performance of HIV Incidence Assays (CEPHIA) showed the Sedia® HIV-1 LAg-Avidity EIA displayed the lowest False Recency Rate of any HIV incidence assay evaluated. Read the assessment
PRODUCT APPLICATIONS
Measure the incidence of HIV-1 as a tool for intervention programs.
Improve resource management and population surveillance.
Evaluate the success of HIV intervention programs.
Identify hot spots of new outbreaks of HIV infections.
FREQUENTLY ASKED QUESTIONS
CONTACT US
Want to know more or have any questions? Send us a message!